WHAT IS TARGETED ALPHA PSMA THERAPY?
Targeted Alpha PSMA Therapy is a targeted, selective internal cellular level radiotherapy to control advanced prostate and cancer. Targeted Alpha PSMA Therapy uses alpha-emitting radioisotopes like Actinium 225 and is a safe, effective therapy with very minimal side-effects. Being highly selective, targeted alpha therapy, often called Magic Bullet therapy has the potential to revolutionize the way metastatic prostate cancer is treated in the future.
The Nuclear Oncology Experts Team operating out of Fortis Memorial & Research Institute (FMRI), Gurugram, Haryana, India was the pioneer of this therapy in India and Asia. The centre is currently the only centre performing this therapy in India on a regular basis.
WHAT ARE THE SIDE-EFFECTS OF TARGETED ALPHA PSMA THERAPY?
The most common side-effect of Targeted Alpha PSMA Therapy is dry mouth (Xerostomia), While some patients may find it distressing, most patients do not report a very significant impact on their lifestyle due to the xerostomia.
There is usually no bone marrow suppression, nor any damage to the kidney or liver functions due to Targeted Alpha PSMA therapy.
WHERE IS THE AC225 SOURCED FROM?
The Actinium 225 is sourced from Mssrs ITG Germany. The product is approved by the European Medicines Association as well as the Indian Pharmacopia. The highly purified peptides are sourced from ABX Germany. The labelling of Actinium 225 with the peptide is done in house using Good Manufacturing Techniques. The highest standards of quality assurance are maintained at every level.
WHAT ARE THE BENEFITS FROM TARGETED ALPHA PSMA THERAPY?
After completing almost 50 treatment cycles at the centre, the Nuclear Oncology Experts Team is extremely excited with the initial results. With each therapy cycle, most of the patients who have undertaken the treatment have experienced a remarkable improvement in their quality of life with reduced symptoms and pain. Apart from this, the team has also seen an associated biochemical response with a fall in serum PSA levels, indicating a reduction in total tumour burden in the body. Most patients also show a prolonged duration of response with a few patients being in near-complete biochemical and clinical remission for over a year. They continue in clinical remission and as more time goes by the impact of Ac225 PSMA Therapy on the overall survival of patients would become clearer.
The team has performed Ga68 PSMA scans before the next due cycles to monitor radiological responses and have witnessed some encouraging results – nearly 70% tumour reduction in a single cycle in some patients.
Pre-therapy PSMA Scan with disease in Prostate Gland, Retroperitoneal Lymph Nodes & Lungs (seen as black spots)
After one cycle of Ac225 PSMA Therapy, the patient had a remarkable reduction in the active tumour from the lungs (black spots in the image on the left), Retroperitoneal Lymph Nodes, as well as shrinkage of tumour in the Prostate Gland.